Abstract
A close interaction of cancer cells with their microenvironment is important for their growth and survival. In this respect, the involvement of inflammatory cells in the initiation, promotion and progression of cancer has pointed to new therapeutic opportunities in the treatment of cancer. The main immune cell types implicated in tumor-associated inflammation are macrophages, dendritic cells, lymphocytes, neutrophils, eosinophils and mast cells. Their precise role in intercellular communication, regulation of tumor inflammation, and to what respect this inflammation contributes to tumor development, are not completely understood. Mast cells are key effector cells in allergic diseases, but it has become apparent that they also contribute to other pathologies, including autoimmune diseases and cancer. Activated mast cells can release many pro-angiogenic and tumor growth stimulatory mediators. Increased numbers of mast cells are found in many tumors and it has been shown that the number of tumor infiltrating mast cells correlate with increased intratumoral microvessel density, enhanced tumor growth and tumor invasion, and poor clinical outcome. Therefore, modulating mast cell recruitment, viability, activity, or mediator release patterns at malignant sites can be of importance to control tumor growth. In this review, we will focus on the contribution of mast cells to tumor development and growth and the possibilities to interfere in mast cell activation and proliferation in the therapy of cancer.
Keywords: Tumor cell, cancer, mast cell, inflammation, c-kit, microenvironment, angiogenesis, stem cell factor
Current Pharmaceutical Design
Title: Mast Cells as Target in Cancer Therapy
Volume: 15 Issue: 16
Author(s): Tom Groot Kormelink, Abulikemu Abudukelimu and Frank A. Redegeld
Affiliation:
Keywords: Tumor cell, cancer, mast cell, inflammation, c-kit, microenvironment, angiogenesis, stem cell factor
Abstract: A close interaction of cancer cells with their microenvironment is important for their growth and survival. In this respect, the involvement of inflammatory cells in the initiation, promotion and progression of cancer has pointed to new therapeutic opportunities in the treatment of cancer. The main immune cell types implicated in tumor-associated inflammation are macrophages, dendritic cells, lymphocytes, neutrophils, eosinophils and mast cells. Their precise role in intercellular communication, regulation of tumor inflammation, and to what respect this inflammation contributes to tumor development, are not completely understood. Mast cells are key effector cells in allergic diseases, but it has become apparent that they also contribute to other pathologies, including autoimmune diseases and cancer. Activated mast cells can release many pro-angiogenic and tumor growth stimulatory mediators. Increased numbers of mast cells are found in many tumors and it has been shown that the number of tumor infiltrating mast cells correlate with increased intratumoral microvessel density, enhanced tumor growth and tumor invasion, and poor clinical outcome. Therefore, modulating mast cell recruitment, viability, activity, or mediator release patterns at malignant sites can be of importance to control tumor growth. In this review, we will focus on the contribution of mast cells to tumor development and growth and the possibilities to interfere in mast cell activation and proliferation in the therapy of cancer.
Export Options
About this article
Cite this article as:
Kormelink Groot Tom, Abudukelimu Abulikemu and Redegeld A. Frank, Mast Cells as Target in Cancer Therapy, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453284
DOI https://dx.doi.org/10.2174/138161209788453284 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
Current Vascular Pharmacology Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Estrogen, Immunity & Autoimmune Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Mucosal Immunity - Basic Principles, Ontogeny, Cystic Fibrosis and Mucosal Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Candidate Genes Implicated in Type 1 Diabetes Susceptibility
Current Diabetes Reviews Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets